anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fraility; It is an age-related biological syndrome. It is characterized by decreased resistance to stressors due to changes in functional reserves and physiological systems.Especially, the increase in the incidence of falls, loss of mobility, dependence in basic life activities, increase in hospitalizations and increased incidence of death make the diagnosis and treatment of frailty important in elderly individuals.

BESTest, which is frequently used in the literature, was modified and Frail'BESTest was developed to detect balance problems in fragile individuals. The test consists of 6 subtitles. These are participation, reaction, movement ability, sensory organization, biomechanical constraints, gait symmetry. When looking at the literature, the Turkish version of Frail'BESTest has not been found. For this reason, the aim of study is to examine the validity and reliability of the Turkish version of Frail'BESTest in elderly individuals and to question the effectiveness of its clinical use and to bring it to the use of other researchers.
When the patient is switching from a 21 day regimen of tablets, she should wait 7 days after her last tablet before she starts Levonorgestrel and Ethinyl Estradiol Tablets She will probably experience withdrawal bleeding during that week. She should be sure that no more than 7 days pass after her previous 21 day regimen. When the patient is switching from a 28 day regimen of tablets, she should start her first pack of Levonorgestrel and Ethinyl Estradiol Tablets on the day after her last tablet. She should not wait any days between packs. The patient may switch any day from a progestin-only pill and should begin Levonorgestrel and Ethinyl Estradiol Tablets the next day. If switching from an implant or injection, the patient should start Levonorgestrel and Ethinyl Estradiol Tablets on the day of implant removal or, if using an injection, the day the next injection would be due. In switching from a progestin-only pill, injection, or implant, the patient should be advised to use a nonhormonal back-up method of birth control for the first 7 days of tablet-taking.
Magnesium may have a significant impact on the development of cancer. However, the relationship between magnesium intake and the risk of colorectal cancer (CRC) is unclear. Therefore, we evaluated the association between magnesium intake and the risk of CRC, and we investigated how the insulin receptor (INSR) rs1799817 variant impacts this relationship. Data from 1,420 CRC patients and 2,840 controls from the Korean National Cancer Centre were analysed. A higher intake of magnesium was associated with a reduced risk of CRC in the total population (odds ratio (OR) = 0.65, 95% confidence interval (CI) = 0.52-0.81). We found that G + carriers of INSR rs1799817 with higher magnesium intake had a significantly lower risk of CRC (p for interaction = 0.003). Our findings indicated that high magnesium intake could be associated with a decreased risk of CRC, and this association could be modified by the INSR rs1799817 variant.
BACKGROUND: Noradrenaline is a standard treatment for hypotension in acute care. The precise effects of noradrenaline on cerebral blood flow in health and disease remain unclear.
METHODS: We systematically reviewed and synthesised data from studies examining changes in cerebral blood flow in healthy participants and patients with traumatic brain injury and critical illness.
RESULTS: Twenty-eight eligible studies were included. In healthy subjects and patients without critical illness or traumatic brain injury, noradrenaline did not significantly change cerebral blood flow velocity (-1.7%, 95%CI -4.7-1.3%) despite a 24.1% (95%CI 19.4-28.7%) increase in mean arterial pressure. In patients with traumatic brain injury, noradrenaline significantly increased cerebral blood flow velocity (21.5%, 95%CI 11.0-32.0%), along with a 33.8% (95%CI 14.7-52.9%) increase in mean arterial pressure. In patients who were critically ill, noradrenaline significantly increased cerebral blood flow velocity (20.0%, 95%CI 9.7-30.3%), along with a 32.4% (95%CI 25.0-39.9%) increase in mean arterial pressure. Our analyses suggest intact cerebral autoregulation in healthy subjects and patients without critical illness or traumatic brain injury., and impaired cerebral autoregulation in patients with traumatic brain injury and who were critically ill. The extent of mean arterial pressure changes and the pre-treatment blood pressure levels may affect the magnitude of cerebral blood flow changes. Studies assessing cerebral blood flow using non-transcranial Doppler methods were inadequate and heterogeneous in enabling meaningful meta-analysis.
CONCLUSIONS: Noradrenaline significantly increases cerebral blood flow in humans with impaired, not intact, cerebral autoregulation, with the extent of changes related to the severity of functional impairment, the extent of mean arterial pressure changes and pre-treatment blood pressure levels.
Standard general anesthesia was applied Patients will be randomly allocated to receive single shot of ESP blocks (Group ESPB), Paravertebral blocks (Group PVB) or (Group ICNB )at T4 and T6 levels according to a random number list that will be generated by a computer and will be stored in sealed envelopes. An independent experienced anesthesiologist will perform the first two blocks or surgeon will perform the third one through the thoracoscope according to the random number. The study coordinator, attending anesthesiologist, data collection resident and the patients will be all blinded to the treatment group assignment. All blocks will be applied on patient's back in a lateral position. Postoperative analgesia regimen consisted of a continuous infusion of iv iboprofen and morphine as a second rescue drug. Demographic data, past medical history, surgical and anesthetic data will be documented. Postoperative pain scores, consumption of analgesia and quality of recovery will be recorded to evaluate the analgesic effect.
The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention. After the 12-month assessment, subjects in the support group will be offered the intervention although this will be out of the scope of this study.
Although our understanding of frailty has evolved and multiple indices have been developed, the impact of burn injuries on long-term health has been overlooked. With over 11 million annual cases globally, burns affect all demographics, although socioeconomic disparities are evident. With survival rates improved, morbidity among survivors is becoming more evident, and shows similarity to predictors of frailty. Some of the chronic effects of burns, including mental health issues and increased risks of disease, mirror frailty markers. Studies show burn survivors have lower life expectancy, independent of burn severity. Integrating burn history into frailty assessments and establishing specialized long-term care can mitigate this frailty risk. Improved interdisciplinary follow-up and research are vital for enhancing burn survivors' quality of life and longevity.
The invention relates to the fields of molecular virology and immunology, in particular to application of a diphtheria toxin non-toxic mutant cross-reacting material 197 (CRM197) or a segment thereof as an intramolecular adjuvant for improving the immunogenicity of a target protein (such as a hepatitis E virus (HEV) capsid protein, an influenza virus M2 protein or an immunogenic segment thereof) fused with the CRM197 or the segment thereof in a fusion protein. The invention also relates to a method for improving the immunogenicity of the target protein (such as the HEV capsid protein, the influenza virus M2 protein or the immunogenic segment thereof). The method comprises the step of performing fusion expression on the CRM197 or the segment thereof and the target protein to form the fusion protein. The invention also relates to the fusion protein containing the CRM197 or the segment thereof and the target protein (such as the HEV capsid protein, the influenza virus M2 protein or the immunogenic segment thereof). The immunogenicity of the target protein is improved by the CRM197 or the segment thereof. The invention also relates to separated nucleic acid for coding the fusion protein, and a host cell containing the nucleic acid. The nucleic acid comprises a structure and a carrier. The invention also relates to application of the fusion protein to preparation of a medicinal composition or a vaccine.
This is an Internet-based, five-branch randomized controlled intervention, enrolling 3,000 adult MSM. The five branches include 1) a control condition receiving no intervention content, 2) a standard text-based prevention webpage, 3) an 8 minute dramatic video addressing sexual risk reduction within the context of alcohol use, 4) a 5 minute documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use, and 5) both videos. After completing the baseline survey, eligible participants who consent to participate in the intervention will be randomly assigned to the control condition or one of the four intervention conditions. The control condition will not include the delivery of any intervention content. All participants (branches 1-5) will be asked to complete a brief post-intervention survey (to measure intentions). All intervention participants will be invited to complete a final 60-day follow-up survey.
Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE: To obtain the subject contrast medium containing a specific brominated perfluorocarbon as an active ingredient, excellent in X-ray shielding properties, having a low accumulating property in the living body, no toxicity and an excellent living body adaptability. CONSTITUTION: This X-ray contrast medium contains a brominated perfluorocarbon of formula I [R<1> , R<2> are each a 2-5C perfluoroalkyl or a ring structure formed by linking the part of formula II in one unit; A is -(CF2 )n - (n is 1-5)], or formula III (R<3> , R<5> are each F or a 1-3C perfluoroalkyl; R<4> is F, Br) as an active ingredient. The object contrast medium is e. g. in the case of imaging an artery or a vein in extremities, injected percutaneously into the artery or the vein. In the case of imaging vena cava or branching arteries in chest or abdominal parts, it is injected e.g. through a percutaneous arterial catheter. In the case of imaging blood vessels in heart or lung, it is injected e. g. through an intracardiac catheter. For the imaging liver, spleen or tumor, it is preferable to inject it intravenously.  Further, the amount of a dose is preferably 5-500ml for one administration.
The safety and preliminary therapeutic efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation rule. Three dose levels of CAR T will be administered in this study: 1x10\^6, 3x10\^6, 1x10\^7 CCT301-59 CAR positive T cells/kg weight, intravenous infusion.
Healthcare object management systems and methods are presented. Health Object Identifiers (HOI) representative of healthcare object ( e.g ., medical records, data, etc.) can be derived from biometric data associated with a patient. HOIs can resolve to a network location where the healthcare object can be accessed. Biometric data, or other types of object data, can be exchanged among computing devices and the healthcare object. On exemplary use of HOIs includes self assembling personal data records as sensor data is obtained.
Hypothermia is a common problem in traumatized patients leading to severe complications such as impaired coagulation, increased rate of wound infections and overall patient discomfort among others. Therefore, the investigators test out the new self warming (via an exothermic reaction) ReadyHeat® blanket device against the currently used cotton wool blanket in terms of effects on the prevention and treatment of hypothermia. Near body core temperature is measured by a sublingual sensor as the "gold standard" of body core temperature measurement - the pulmonary artery catheter - is too invasive and not suited for this collective of patients in the emergency room setting. Blanket use will be randomized. Temperature will be taken at emergency room admission, after 15, 30 and 45 minutes of treatment as well as right before handing the patient over to the next caring unit (ICU, IMC, operating theatre etc.). If treatment time is shorter than expected measurement will stop at the latest possible point. Blankets will be applied to the patient once admission in the emergency room is complete and will only be lifted for interventions.
The Copper IUD (Cu-IUD) is the most widely used IUD in the world, and its use in the United States (US) is on the rise. The Cu-IUD is considered one of the most effective contraception methods, being as effective as permanent sterilization but having the convenience of being reversible should a woman decide to conceive.2 The Copper 380A (TCu380A) is the only Cu-IUD available in the US; of all Cu-IUDs, the TCu380A is considered the most effective. Despite its increasing popularity in the US, studies indicate that bleeding irregularities and dysmenorrhea are common reasons for method discontinuation. Some evidence suggests that non-steroidal anti-inflammatory medications (NSAIDs) can help improve bleeding during Cu-IUD use. However, these studies did not examine NSAID use with the TCu380A specifically, nor did they evaluate readily available NSAIDs such as over-the-counter naproxen. For this reason, the investigators propose a pilot trial in which new TCu380A users complaining of heavy or prolonged menstrual bleeding or spotting after 1 month of use are randomized to naproxen or placebo to be taken the first 7 days of menstruation for three consecutive cycles, and then observed for one cycle without treatment. The number of bleeding/spotting days will be compared using Student t-test. In addition to assessing how well naproxen reduces incidence and amount of bleeding, the investigators will also assess the use of naproxen and TCu380A on quality of life, sexual function, method satisfaction, menstrual pain, and adverse events. By measuring these variables, the investigators will assess both positive and negative consequences of TCu380A use, ensuring that harm does not outweigh benefits.
Composition including cyclamate in an amount sufficient to inhibit bacterial growth and/or virulence for use in a method of treating and/or preventing infection of a wound. The infection may be bacterial and caused by Pseudomonas aeruginosa, Acinetobacter baumannii, Enterococcus faecalis, Klebsiella pneumoniae, Stenotrophomonas maltophilia or Enterobacter. The composition may inhibit biofilm formation and/or bacterial motility. The cyclamate may be sodium cyclamate. The composition may be formulated for application to a patients skin (e.g. for application to a wound; or as a liquid, cream ointment, gel or hydrogel), for inhalation (e.g. in an aerosolised or dry powder form) or for intravenous administration. The composition may be included in a wound dressing for topical application.
The invention relates to an application of a beta chemokine receptor inhibitor or a composition comprising the beta chemokine receptor inhibitor in preparing a medicine used for treating inherited retinal diseases or for protecting inherited retinal degeneration photoreceptor cells. The beta chemokine receptor inhibitor blocks the combination of beta chemokine and the receptor thereof, and further blocks the signaling pathways after receptor activation and the caused oxidative damage reaction, so as to treat the inherited retinal diseases or to protect the inherited retinal degeneration photoreceptor cells. Preferably, the beta chemokine receptor inhibitor is administrated through vitreous cavity injection. Preferably, the beta chemokine receptor inhibitor is selected from met-RANTES. Preferably, the disease is inherited retinal degeneration. The intervention of the beta chemokine receptor inhibitor against inherited retinal degeneration diseases is substantially made earlier. Therefore, the application is an ideal means for treating early-stage RP. According to the application, a specific gene defect type is not considered. The beta chemokine receptor inhibitor provided by the invention has the advantages such as better practicality, wider application, and the like.
A large percentage of caffeine users in the general population (56%) report a persistent desire or unsuccessful efforts to stop or reduce caffeine consumption. The aim of Study 1 is to recruit and identify individuals who are interested in receiving treatment to reduce or quit caffeine consumption. Individuals will be recruited from Baltimore, MD and surrounding communities via flyers and newspaper and radio advertisements. Those who are eligible will be invited to come to the Behavioral Pharmacology Research Unit located on the Johns Hopkins Bayview Medical Center campus in Baltimore, MD. After consent is obtained at intake (consent form A), a series of questionnaires will be completed (e.g., demographics, caffeine history, medical and psychiatric history, mood), followed by a structured clinical interview that will assess caffeine use and dependence. Individuals who meet eligibility criteria will be offered the opportunity to receive assistance to reduce or quit caffeine. Those who consent (consent form B) to enroll in the second phase of the project will be randomly assigned to one of two conditions: 1) immediate treatment or 2) delayed treatment. The conditions will be identical with the exception of a 6 week delay for the delayed treatment group. Participants will receive a caffeine reduction and cessation treatment manual during a brief treatment session at week 1. Treatment progress will be assessed during a study session approximately 7 weeks post-treatment, during a telephone interview approximately 8 weeks post-treatment, and during a follow-up telephone call approximately 27 weeks after the treatment session. Progress will be assessed via questionnaires, food diaries, and salivary caffeine measures.
The study process lasts for a total of 90 days, including the screening period, intervention period, and follow-up period. During the intervention period, the experimental group is treated with Urinary Kallidinogenase, while the control group is treated with placebo for 10 days. Both groups receive routine clinical treatment. All patients are followed up until the 90th day after stroke. The sample size of the study is 630 patients. The ratio of the experimental group to the control group is 1:1.
Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
The invention discloses dealcoholic tea and a preparation method thereof, and relates to a tea substitute or medical preparation mainly prepared by plant materials. The invention provides a dealcoholic tea with favorable dealcoholic effect and a preparation method thereof. The dealcoholic tea is prepared by the following raw materials in mass ratio: 20-30 parts of tea, 10-20 parts of medicated leaven, 3-6 parts of costus root, 3-9 parts of orange peel, 30-40 parts of flower of kudzuvine, 10-15 parts of rhizoma alismatis and 10-20 parts of Hovenia dulcis. The tea can be green tea, black tea, Oolong tea, Pu-Erh tea and the like. The preparation method is realized by mixing and pulverizing all the raw materials. When being taken, the user can drink the tea with hot water, and the dosage is 10-20 g each time. The dealcoholic tea can also be prepared in the form of tablets, pills, water aqua and the like. The dealcoholic tea has favorable dealcoholic effect for insobriety, drunk dizziness and drunk vomit and the like, and is an effective dealcoholic prescription for warming the spleen and stomach, removing alcoholic dyspepsia and clearing away heat and promoting diuresis.
This study aims to investigate the association between chromosomal polymorphisms and abnormalities in male reproductive health. Within the period from January 2018 to December 2022, a cohort of 10,827 males seeking fertility services at our reproductive center was selected for inclusion in this study. Peripheral blood chromosomal karyotype analysis was conducted for each participant to identify carriers of chromosomal polymorphisms, who were subsequently categorized into a polymorphism group. Additionally, a control group was constituted by randomly selecting 1,630 patients exhibiting normal chromosomal karyotypes. The study conducted statistical analyses to compare clinical outcomes between the two groups, focusing on infertility, history of spontaneous miscarriage in partners, anomalies in reproductive development, fetal abnormalities, and sperm quality metrics. (1) Among the cohort of 10,827 males, chromosomal polymorphisms were identified in 1,622 participants, yielding a detection rate of 14.98%. This rate is significantly elevated in comparison to the baseline prevalence of 1.77% observed in the general population. (2) The predominant variant among these polymorphisms was related to the Y chromosome, accounting for 1,082 cases (66.71% of the polymorphic findings), corresponding to a detection rate of 9.99%. This is markedly higher than the approximate 0.09% prevalence noted within a normative demographic. (3) Statistical analysis revealed significant disparities between the chromosomal polymorphism group and the control group in several clinical outcomes. Notably, the rates of spontaneous abortion (18.06% vs. 1.35%), fetal anomalies (1.97% vs. 0.25%), and poor sperm quality (41.74% vs. 7.18%) were markedly higher in the polymorphism group. Additionally, incidences of testicular dysgenesis (2.28% vs. 0.92%) and hypogonadism in partners (0.62% vs. 0.37%) also demonstrated significant differences, underscoring the potential reproductive implications of chromosomal polymorphisms. The study establishes a significant link between chromosomal polymorphisms and critical reproductive outcomes, including male infertility, spontaneous miscarriages in partners, fetal anomalies, and reduced sperm quality. These findings highlight the clinical relevance of chromosomal polymorphisms in reproductive health assessments and suggest the necessity for their consideration in the diagnostic and therapeutic strategies for male reproductive disorders.
NEW MATERIAL:A compound of formula I (R<1>, R<2> are CH3OCH2, or they incorporate to form formula II; R<3> is aromatic or heterocyclic group which may be substituted; n is 5 or 6). EXAMPLE:7-(4-Methoxyphenyl)-7-(3,5,6-trimethyl-1, 4-benzoquinon-2-yl)-heptanohy droxamic acid. USE:Medicine. It is used to suppress the rejection after transplant of organs, or as a remedy or prophylactic for cancer and self-immune diseases. Further, it has actions to inhibit cell proliferation and new formation of blood vessels, moreover action to inhibit the formation of 5-lipoxygenase metabolites and used as an antiasthmatic, antiallergic or cerebral circulation improver with extremely reduced toxicity and side-effects. PREPARATION:A compound of formula III is allowed to react with an agent for activating carboxylic acid such as oxalyl chloride in a solvent and the product is allowed to react with hydroxylamine in a solvent to give the compound of formula I.